Lindholm J, Juul S, Jørgensen J O, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J
Department of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark.
J Clin Endocrinol Metab. 2001 Jan;86(1):117-23. doi: 10.1210/jcem.86.1.7093.
The main purpose was to assess the incidence and late outcome of Cushing's syndrome, particularly in Cushing's disease. Information for all patients diagnosed with Cushing's syndrome during an 11-yr period in Denmark was retrieved. The incidence was 1.2-1.7/million.yr (Cushing's disease), 0.6/million.yr (adrenal adenoma) and 0.2/million.yr (adrenal carcinoma). Other types of Cushing's syndrome were rare. In 139 patients with nonmalignant disease, 11.1% had died during follow-up (median, 8.1 yr; range, 3.1-14.0), yielding a standard mortality ratio (SMR) of 3.68 [95% confidence interval (CI), 2.34-5.33]. The SMR was partly attributable to an increased mortality within the first year after diagnosis. Eight patients died before treatment could be undertaken. The prognosis in patients with malignant disease was very poor. Patients in whom more than 5 yr had elapsed since initial surgery were studied separately, including a questionnaire on their perceived quality of health. In 45 patients with Cushing's disease who had been cured through transsphenoidal neurosurgery, only 1 had died (SMR, 0.31; CI, 0.01-1.72) compared with 6 of 20 patients with persistent hypercortisolism after initial neurosurgery (SMR, 5.06; CI, 1.86-11.0). In patients with adrenal adenoma, SMR was 3.95 (CI, 0.81-11.5). The perceived quality of health was significantly impaired only in patients with Cushing's disease and appeared independent of disease control or presence of hypopituitarism. It is concluded that 1) Cushing's syndrome is rare and is associated with increased mortality, in patients with no concurrent malignancy also; 2) the excess mortality was mainly observed during the first year of disease; and 3) the impaired quality of health in long-term survivors of Cushing's disease is not fully explained.
主要目的是评估库欣综合征的发病率和晚期转归,尤其是库欣病的情况。检索了丹麦11年间所有诊断为库欣综合征患者的信息。发病率为每年1.2 - 1.7/百万(库欣病)、每年0.6/百万(肾上腺腺瘤)和每年0.2/百万(肾上腺皮质癌)。其他类型的库欣综合征较为罕见。在139例非恶性疾病患者中,11.1%在随访期间死亡(中位数8.1年;范围3.1 - 14.0年),标准化死亡比(SMR)为3.68 [95%置信区间(CI),2.34 - 5.33]。该SMR部分归因于诊断后第一年死亡率的增加。8例患者在能够进行治疗前死亡。恶性疾病患者的预后非常差。对初次手术后已过去5年以上的患者进行了单独研究,包括一份关于他们自我感知健康质量的问卷。在45例经蝶窦神经外科手术治愈的库欣病患者中,仅1例死亡(SMR,0.31;CI,0.01 - 1.72),而初次神经外科手术后仍存在持续性高皮质醇血症的20例患者中有6例死亡(SMR,5.06;CI,1.86 - 11.0)。肾上腺腺瘤患者的SMR为3.95(CI,0.81 - 11.5)。仅库欣病患者的自我感知健康质量受到显著损害,且似乎与疾病控制或垂体功能减退的存在无关。结论为:1)库欣综合征罕见,且即使在无并发恶性肿瘤的患者中也与死亡率增加相关;2)额外的死亡率主要在疾病的第一年观察到;3)库欣病长期存活者健康质量受损的原因尚未完全明确。